Navigation Links
Dutasteride not a cost-effective way to prevent prostate cancer in some men
Date:2/8/2011

DALLAS Feb. 8, 2011 The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

In a study available in the January issue of Cancer Prevention Research, investigators found that the medication, at an annual cost of $1,400, is impractical when compared to the marginal impact on survival and quality of life in at-risk groups. The drug is indicated for the treatment of enlarged prostates but also is widely prescribed for chemoprevention.

"Because prostate cancer is the most common cancer in men, the implications of this data are significant since there could be millions of men who would be eligible for anti-cancer drugs," said Dr. Yair Lotan, associate professor of urology at UT Southwestern. "Prior to instituting a chemoprevention strategy to a large population, the utility and cost need to be well understood. Whether a medication improves survival, how it affects quality of life, and what its financial implications will be are all critical issues. Because dutasteride typically is prescribed for the lifetime of the patient, and therefore taken daily for decades, the cost issue is particularly relevant."

Prior research has shown that dutasteride reduced the relative risk of prostate cancer over a four-year period by 22.8 percent, but questions have remained about its cost-effectiveness. The current study analyzed the lifetime health-related costs of the drug in patients at greater risk of developing prostate cancer and compared them to other factors, such as quality and length of life.

Dr. Lotan and his colleague, Dr. Robert Svatek of UT Health Science Center at San Antonio, used a Markov probability model to compare the lifetime cost of taking dutasteride with no therapy. They used data from a previous trial and studies that evaluated outcomes of patients with prostate cancer, including treatment-related complications to create the model. The primary outcome was measured in quality-adjusted life years (QALY), which takes into account both quality and quantity of life.

"The study found that dutasteride was not cost-effective for chemoprevention unless and until a strategy is developed for targeting very high-risk patients and the cost of the drug decreases," said Dr. Lotan. "For the average man, the drug provides minimal survival benefits, and the reduction on treatment-related complications does not compensate for the high costs of every man taking the drug for many years."


'/>"/>

Contact: Rachel Skei Donihoo
rachel.donihoo@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. European Urology: Editorial about REDUCE trial underlines value of dutasteride
2. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
3. Web-based questionnaire can be cost-effective tool for survey responses
4. Testing African couples for HIV is cost-effective prevention strategy
5. Wider statin use could be cost-effective preventive measure, Stanford study finds
6. Centralized health care more cost-effective, offers better access to preventive services
7. Trauma center care cost-effective
8. UNC physician authors editorial on cost-effectiveness study for colon cancer screening
9. Colorectal cancer screening in Canada is cost-effective
10. Antiviral therapy during compensated cirrhosis most cost-effective approach
11. Hospital Focus 5 Announces Contract with Connecticut Hospital to Improve Quality, Productivity and Cost-Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Looking for a last-minute Valentine’s Day ... tips of your toes. Foot massage, whether administered by a professional masseuse or a ... The American Board of Multiple Specialties in Podiatry (ABMSP) has taken the ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... from across the country gathered at the La Valencia Hotel in San Diego, ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with the ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot ... 2015 Best in KLAS: Software & Services for HIT Implementation Support & Staffing ... report independently ranks vendor performance by healthcare executives, managers and clinicians representing over ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a ... drop zone to the next using Colorize's dynamic moving camera. Colorize is perfect for ... includes a 3D slideshow environment with 1 to 5 focus points per scene, stage ...
(Date:2/5/2016)... ... , ... Calls Blacklist has just been updated by mobile app developer Vlad ... has fixed known bugs within the app. Calls Blacklist allows its users to only ... any of their device’s battery power or memory. It provides a powerful call blocker ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... WARSAW, Ind. , Feb. 5, 2016  Zimmer ... the pricing of the previously announced underwritten secondary offering ... of its stockholders, consisting of affiliates of Blackstone and ... public at an initial price of $96.45 per share. ... of the offering.  Neither Zimmer Biomet nor any of ...
(Date:2/5/2016)... France , Germany , Italy ... ). It includes a 10-year epidemiology forecast for the total prevalent ... sex in these markets. GD epidemiology report is written and developed by ... and market-driven, providing expert analysis of disease trends in the 7MM. ... Italy , Spain , UK, and ...
(Date:2/4/2016)... Feb. 4, 2016  The Senior Care Pharmacy ... Reform Committee Chairman Jason Chaffetz (R-UT) ... today,s hearing , "Developments in the Prescription ... and growing questions about abusive pharmacy benefit manager ... (R-UT) and Ranking Member Elijah Cummings (D-MD) are ...
Breaking Medicine Technology: